Irreversible Leukoencephalopathy After Reduced-intensity Stem Cell Transplantation in a Dyskeratosis Congenita Patient With TINF2 Mutation

被引：8

作者：

Isoda, Takeshi ^{[1
]}

Mitsuiki, Noriko ^{[1
]}

Ohkawa, Teppei ^{[1
]}

Kaneko, Setsuko ^{[1
]}

Endo, Akifumi ^{[1
]}

Ono, Toshiaki ^{[1
]}

Aoki, Yuki ^{[1
]}

Tomizawa, Daisuke ^{[1
]}

Kajiwara, Michiko ^{[2
]}

Araki, Satoshi ^{[1
]}

Nagasawa, Masayuki ^{[1
]}

Morio, Tomohiro ^{[1
]}

Takagi, Masatoshi ^{[1
]}

Mizutani, Shuki ^{[1
]}

机构：

[1] Tokyo Med & Dent Univ, Dept Pediat & Dev Biol, Yushima, Tokyo 1138519, Japan

[2] Tokyo Med & Dent Univ, Hosp Blood Transfus Ctr, Yushima, Tokyo 1138519, Japan

来源：

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY | 2013年 / 35卷 / 04期

关键词：

dyskeratosis congenita; TINF2; hematopoietic stem cell transplantation; complication; sequelae; encephalopathy; REVERSIBLE ENCEPHALOPATHY SYNDROME; POSTERIOR; CHILDREN; LENGTH;

D O I：

10.1097/MPH.0b013e318279e5ca

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Hematopoietic stem cell transplantation (HSCT) for dyskeratosis congenita (DC) is challenging due to severe treatment-related adverse effects. Development of pulmonary fibrosis or veno-occlusive disease is well described in DC. However, neurological complication after HSCT has not been reported. A 9-year-old Japanese male with DC harboring the TINF2 mutation received reduced-intensity HSCT. Unfortunately, patient developed posterior reversible encephalopathy syndrome-like symptoms plausibly result by combination of thrombotic microangiopathy, graft-versus-host disease, and persistent hypertension and has been persisted mental retardation. Therefore, to decrease risk in DC cases after HSCT, strict control of hypertension, graft-versus-host disease, and thrombotic microangiopathy is required.

引用

页码：E178 / E182

页数：5

共 21 条

[1] Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita [J].

Alter, Blanche P. ;

Baerlocher, Gabriela M. ;

Savage, Sharon A. ;

Chanock, Stephen J. ;

Weksler, Babette B. ;

Willner, Judith P. ;

Peters, June A. ;

Giri, Neelarn ;

Lansdorp, Peter M. .

BLOOD, 2007, 110 (05) :1439-1447

[2] Late death after unrelated-BMT for dyskeratosis congenita following conditioning with alemtuzumab, fludarabine and melphalan [J].

Amarasinghe, K. ;

Dalley, C. ;

Dokal, I. ;

Laurie, A. ;

Gupta, V. ;

Marsh, J. .

BONE MARROW TRANSPLANTATION, 2007, 40 (09) :913-914

[3] Flow cytometry and FISH to measure the average length of telomeres (flow FISH) [J].

Baerlocher, Gabriela M. ;

Vulto, Irma ;

de Jong, Gary ;

Lansdorp, Peter M. .

NATURE PROTOCOLS, 2006, 1 (05) :2365-2376

[4] Posterior reversible encephalopathy syndrome, part 1: Fundamental imaging and clinical features [J].

Bartynski, W. S. .

AMERICAN JOURNAL OF NEURORADIOLOGY, 2008, 29 (06) :1036-1042

[5] Fatal diffuse capillaritis after hematopoietic stem-cell transplantation for dyskeratosis congenita despite low-intensity conditioning regimen [J].

Brazzola, P ;

Duval, M ;

Fournet, JC ;

Gauvin, F ;

Dalle, JH ;

Champagne, J ;

Champagne, MA .

BONE MARROW TRANSPLANTATION, 2005, 36 (12) :1103-1105

[6] Telomere maintenance and human bone marrow failure [J].

Calado, Rodrigo T. ;

Young, Neal S. .

BLOOD, 2008, 111 (09) :4446-4455

[7] Dyskeratosis congenita: Advances in the understanding of the telomerase defect and the role of stem cell transplantation [J].

de la Fuente, J. ;

Dyskeratosis, Dokal I. .

PEDIATRIC TRANSPLANTATION, 2007, 11 (06) :584-594

[8] Disease-specific hematopoietic cell transplantation: nonmyeloablative conditioning regimen for dyskeratosis congenita [J].

Dietz, A. C. ;

Orchard, P. J. ;

Baker, K. S. ;

Giller, R. H. ;

Savage, S. A. ;

Alter, B. P. ;

Tolar, J. .

BONE MARROW TRANSPLANTATION, 2011, 46 (01) :98-104

[9] Dyskeratosis Congenita [J].

Dokal, Inderjeet .

HEMATOLOGY-AMERICAN SOCIETY HEMATOLOGY EDUCATION PROGRAM, 2011, :480-486

[10] Thrombomodulin: protectorate God of the vasculature in thrombosis and inflammation [J].

Ito, T. ;

Maruyama, I. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 :168-173

← 1 2 3 →